Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
C. He, L. Zheng, Y. Xu, M. Liu, Y. Li, J. Xu (Shenzhen, Guangzhou, China). Noninvasive detection of EGFR T790M mutation in gefitinib resistant non-small cell lung cancer using mutant-enriched PCR. Eur Respir J 2013; 42: Suppl. 57, 2900

Member's Comments

No comment yet.

Related content which might interest you: Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Validation of PNA-LNA PCR clamp assay for detection of EGFR exon 19 and 21 mutations in various types of clinical non-small cell lung cancer specimens Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Quantitative detection of ALK rearrangements using droplet digital PCR (ddPCR) in liquid biopsies of patients with non-small cell lung cancer (NSCLC) Source: International Congress 2016 – New genomic targets in pulmonary disease Year: 2016 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015 Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 RT-PCR expression of EML4-ALK oncogene in Bulgarian patients with non-small cell lung cancers Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Loss of heterozygosity of PTEN in patients with non-small cell lung cancer treated and not treated with neoadjuvant chemotherapy Source: Annual Congress 2013 –Genetics and genomics of lung disease Year: 2013 Allele-specific real-time PCR detection of EGFR exon 19 and 21 mutations in various clinical non-small cell lung cancer specimens Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 A tissue microarray analysis on the role of chromosome 7 multiplication regarding the EGFR expression in non-small cell lung carcinomas Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013